The Quantellect read.As of Nov 19, 2026, 7 active firms cover Orchestra BioMed Holdings Inc: 7 rate it Buy or better, 0 sit at Neutral, and 0 rate it Sell or worse, a buy consensus. Targets range widely, $10.00 to $20.00 (about 2.0x), a sign of real disagreement on valuation. The average target of $12.33 sits 65% above the current $7.47. The rating mix has stayed broadly stable, with Buy-side ratings edging up from 6 to 7 over recent months. On the fundamentals, the Street sees consensus EPS building from about $-0.31 next quarter toward $-1.27 the year after.Descriptive synthesis of third-party analyst data, not a Quantellect rating or recommendation.
ANALYST CONSENSUS7 active firms
Buy
Strong Buy00%
Buy7100%
Neutral00%
Sell00%
Strong Sell00%
Based on 7 active firms as of Nov 19, 2026 (365-day activity window).
12-MONTH PRICE TARGET
$12.33
+65.1% upside
Average target across 6 active firms as of Nov 19, 2026 vs $7.47 current
Highest Target$20.00
Average Target$12.33
Lowest Target$10.00
Detailed analyst forecasts for OBIO
Showing 1–7 of 7 named analysts shown · 7 active firms in the rating projection
As of Nov 19, 2026, 7 of 7 active firms rate OBIO a Buy (0 Neutral, 0 Sell). Historical months are month-end active-firm counts; the current month uses its actual as-of date.
OBIO EPS & revenue forecast
EPS · NEXT QUARTER
$-0.31
Range $-0.33 – $-0.28 · 3 analysts · -219% YoY
Next period, 3 analysts expect Orchestra BioMed Holdings Inc. to earn $-0.31 a share (range $-0.33 – $-0.28), versus $0.26 a year earlier. Full-year consensus is $-1.33, growing to $-1.27 the year after.
REVENUE · NEXT QUARTER
$102.2K
Range $90.0K – $121.0K · 3 analysts
Revenue is expected to reach $102.2K (range $90.0K – $121.0K). Full-year consensus is $393.2K, rising to $600.1K next year.
Top analysts covering Orchestra BioMed Holdings Inc.
Ranked by each analyst's overall Quantellect track record across all the stocks they cover, shown with their current call on OBIO.
#1
Keay Nakae
Chardan Capital · Rank #130
Buy
$20.00+167.7% to target
Overall win rate
41%
+ Follow
#2
Yi Chen
HC Wainwright & Co. · Rank #350
Buy
$10.00+33.9% to target
Overall win rate
34%
+ Follow
#3
Matt Miksic
Barclays · Rank #543
Buy
$13.00+74.0% to target
Overall win rate
27%
+ Follow
#4
Matt O'Brien
Piper Sandler · Rank #561
Buy
$10.00+33.9% to target
Overall win rate
25%
+ Follow
#5
MT
Marie Thibault
BTIG
Buy
$10.00+33.9% to target
Coverage
—
+ Follow
OBIO stock forecast FAQ
What is OBIO's average 12-month price target?+
The 6 active firms with a live target average $12.33 for Orchestra BioMed Holdings Inc. over the next 12 months, ranging from a $20.00 high to a $10.00 low, as of Nov 19, 2026.
Is OBIO stock a Buy, Sell or Neutral right now?+
The current consensus is Buy. Of the 7 active firms as of Nov 19, 2026, 7 rate it Buy or Strong Buy, 0 rate it Neutral, and 0 rate it Sell or Strong Sell.
What are the highest and lowest price targets for OBIO?+
The Street-high target is $20.00 (Chardan Capital), and the Street-low is $10.00 (BTIG). The average of all 6 active-firm targets is $12.33.
How many active Wall Street firms cover OBIO?+
7 active firms have a recognized rating on Orchestra BioMed Holdings Inc. as of Nov 19, 2026, and 6 active firms carry a live 12-month price target.
Who is the most accurate analyst covering OBIO?+
Among analysts who currently cover OBIO, Keay Nakae of Chardan Capital has the strongest overall Quantellect track record (Rank #130). Their current call is Buy with a $20.00 target.
What is Orchestra BioMed Holdings Inc.'s projected EPS for next quarter?+
The consensus estimate is $-0.31 per share (range $-0.33 – $-0.28) across 3 analysts. Full-year EPS is projected at $-1.33, rising to $-1.27 the following year.
How much revenue is Orchestra BioMed Holdings Inc. expected to report next quarter?+
Consensus revenue is $102.2K (range $90.0K – $121.0K). Full-year revenue is projected at $393.2K, growing to $600.1K next year.
Have analysts been upgrading or downgrading OBIO lately?+
As of Nov 19, 2026, 7 of 7 active firms rate OBIO a Buy (0 Neutral, 0 Sell). Historical months are month-end active-firm counts; the current month uses its actual as-of date.
How are the analysts on this page ranked?+
By each analyst's overall Quantellect track record — a sample-adjusted measure of how accurate their calls have been across every stock they cover. We do not rank on their OBIO calls alone, since a single stock is too small a sample to be reliable.
Which data on this page is live, and how often does it update?+
Price and daily change are 15-minute delayed market data. Analyst ratings, targets, consensus and earnings estimates are aggregated from multiple data providers and refresh daily.
Disclaimer: Ratings, price targets, consensus and earnings estimates on this page describe third-party analyst research aggregated from multiple data providers and refreshed daily; price and daily change are 15-minute delayed. These are historical opinions, not recommendations, and nothing on this page, including The Quantellect read, is a rating, a price target, or investment advice from Quantellect. Always do your own research and consult a licensed financial advisor before making investment decisions.